GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for Immune Profiling, Antibody Discovery and Vaccine Design.

Read the full press release.